Breaking News

Genentech to Acquire Seragon Pharmaceuticals

July 2, 2014

Gains portfolio of next-gen SERDs to treat breast cancer

Genentech, a member of the Roche Group, has entered an agreement to acquire Seragon Pharmaceuticals, a privately-held biotechnology company based in San Diego, for $725 million in cash upfront, plus additional payments of as much as $1 billion in potential milestones. Seragon has a portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer.
As much as 60% of breast cancers depend on the hormone estrogen and the estrogen receptor to grow and spread. Seragon’s lead candidate, ARN-810, is currently in Phase I trials in patients who have hormone receptor-positive breast cancer and have failed current hormonal agents.
“This year, breast cancer will claim the lives of nearly 40,000 women in the United States, and up to half of these women will have a disease that is driven by the estrogen receptor,” said Richard Scheller, Ph.D., executive vice president and head of Genentech Research and Early Development. “We believe these investigational oral SERDs could one day redefine the standard of care for hormone receptor-positive breast cancer.”

The transaction, subject to customary closing conditions, is expected to close in 3Q14. Once completed, Seragon’s portfolio will be integrated into Genentech Research and Early Development.

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.